In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Ziopharm Oncology (NASDAQ: ZIOP), with a price target of $5.50. The company’s shares closed on Friday at $4.37.
“We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 5.3% and a 39.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, Eleven Biotherapeutics, and IntelGenx Technologies.
Ziopharm Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.74 and a one-year low of $3.33. Currently, Ziopharm Oncology has an average volume of 1.12M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer and graft-versus-host-disease.